Evgeny Mikhailovich Belilovsky

Evgeny Mikhailovich Belilovsky

Auto-generated profile, based on publicly available information

Evgeny Mikhailovich Belilovsky

Moscow Research and Clinical Center for Tuberculosis Control

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MSM V Sinitsyn
M V Sinitsyn
MKM V Kalinina
M V Kalinina
EBE M Belilovskiy
E M Belilovskiy
AGA S Galstyan
A S Galstyan
MRMikhail Reshetnikov
Mikhail Reshetnikov
DPD V Plotkin
D V Plotkin
Aim. Study of the current state of problems of treatment of patients with tuberculosis based on literature data and their own experience. Materials and methods. In the Russian Federation, the number and proportion of patients with co-infection with HIV/tuberculosis continues to increase against the background of improvement in the main epidemiological indicants for tuberculosis. In 2017, 20.9% of newly diagnosed tuberculosis patients had HIV infection. The combination of the two infections significantly complicates the further improvement of the situation with tuberculosis, and the appearance of drug-resistant strains of Mycobacterium tuberculosis sometimes completely neutralizes the results of chemotherapy. The article describes the schemes of modern tuberculosis chemotherapy taking into account HIV/tuberculosis co-infection, as well as MDR in combination with surgical treatment methods, as well as analyzes the data of epidemiological monitoring of treatment of 1115 tuberculosis patients newly diagnosed in 2017 in Moscow, 360 tuberculosis patients with MDR MBT (cohort 20132014), the results of treatment with the use of new chemotherapy regimens for tuberculosis (bedaquiline, linezolid, moxifloxacin) in 36 patients, the effectiveness and safety of surgical methods in 192 patients. Results. The application of new individualized anti-TB chemotherapy schedules in patients with HIV co-infection/tuberculosis with MDR-MBT has allowed to improve the treatment efficacy. The surgical intervention combined with modern chemotherapy regimens in patients with HIV/tuberculosis co-infection with MDR MBT has been proved to be effective and safe, contributes to the improving the results of treatment for this category of patients. Conclusion. The confluence of two global problems of co-infection HIV/TB and MDR TB, significantly prevents from the end of the tuberculosis epidemic in the world. At the same time, advances in the development and implementation of new anti-TB drugs and surgical treatment methods give hope for significant progress for resolving this situation.

30 June 2022 in Infectious Disease Modelling
Verified
Journal Article
Open access
KAKonstantin Konstantinovich Avilov
Konstantin Konstantinovich Avilov
ARAlexei Alexeevich Romanyukha
Alexei Alexeevich Romanyukha
EBEvgeny Mikhailovich Belilovsky
Evgeny Mikhailovich Belilovsky
SBSergey Evgenevich Borisov
Sergey Evgenevich Borisov
Little is known about the dynamics of the early stages of untreated active pulmonary tuberculosis: unknown are both the rates of progression and the model “scheme”. The “parallel” scheme assumes that infectiousness of tuberculosis cases is effectively predefined at the onset of the disease, and the “serial” scheme considers all cases to be non-infectious at the onset, with some of them later becoming infectious.

14 September 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
DID A Ivanova
D A Ivanova
EBE M Belilovskiy
E M Belilovskiy
EBE M Bogorodskaya
E M Bogorodskaya
MRMikhail Reshetnikov
Mikhail Reshetnikov
DPD V Plotkin
D V Plotkin
VAV B Avdentova
V B Avdentova
Aim. To study the association of comorbidities and treatment outcomes in tuberculosis (TB) patients. Materials and methods. A retrospective study includes all TB patients aged 18 years and older registered for treatment in Moscow in period 2021 the end of the 3rd quarter of 2022 using data of regional epidemiological TB monitoring system, a total of 3039 patients. The frequency and spectrum of comorbidities, its impact on the risk of adverse treatment outcome (ATO) and mortality using univariate and regression analysis were assessed. Results. Comorbidities were identified in 1528 (50.3%) patients (95% confidence interval – CI 48.5–52.1); HIV infection (18.0%), chronic nonspecific lung disease (9.6%) and cardiovascular disease (8.2%) were predominant. The presence of comorbid pathology increased the odds of uneffective treatment (odds ratio – OR 2.56, 95% CI 2.22–3.03) and death (OR 2.45, 95% СI 1.67–3.59). Independent risk factors for ATO were HIV infection (OR 4.10, 95% CI 3.36–5.10), substance use (OR 2.57, 95% CI 1.70–3.66), chronic nonspecific lung disease (OR 1.39, 95% CI 1.04–1.88), diabetes mellitus (OR 1.69, 95% CI 1.15–2.48), liver pathology (OR 2.10, 95% CI 1.46–3.03), mental illness (OR 2.01, 95% CI 1.32–3.06). The death rate was 13.4%; the most significant predictors of mortality were HIV infection (OR 3.89, 95% CI 2.42–6.22) and liver disease (OR 1.90, 95% CI 1.27–2.82). A comorbidome model was constructed to assess the importance of different comorbidities for patient prognosis. Conclusion. The presence of comorbidity (predominantly HIV infection and liver disease) is a significant risk factor for ATO and mortality in TB patients, which should be taken into account when organizing and providing TB care to comorbid patients.

1 January 2020 in Clinical and Experimental Surgery. Petrovsky journal
Verified
Journal Article
Closed access
FMFavorov M.O.
Favorov M.O.
DIDiaPrep System Inc.
DiaPrep System Inc.
BEBelilovsky E.M.
Belilovsky E.M.
TATursynbaeva A.S.
Tursynbaeva A.S.
ISIsmailov Sh.Sh.
Ismailov Sh.Sh.
NPNational Research Center of Phthisio-Pulmonology
National Research Center of Phthisio-Pulmonology